Glenmark and Helsinn Group to Anti-Nausea Drug in India and Nepal
Mumbai-based Glenmark Pharmaceuticals Ltd., and Switzerland’s Helsinn Group, have announced that they have entered into an exclusive licensing agreement to introduce Akynzeo, an oral fixed combination of netupitant (300-mg) and palonosetron (0.5-mg) in capsule form in India and Nepal. The drug is used for prevention of chemotherapy-induced nausea and vomiting (CINV).
The licensing agreement represents Helsinn’s first such agreement in India, and Glenmark will have exclusive marketing rights for the drug in India and Nepal. Glenmark has received marketing approval for it from the Central Drugs Standard Control Organization (CDSCO).
Akynzeo is the first and only combination anti-emetic prophylaxis with high complete response rates for five days in cancer chemotherapy treated patients. Delayed nausea is still a problem for up to 82% of patients receiving MEC (Moderately Emetogenic Chemotherapy) and HEC (Highly Emetogenic Chemotherapy), representing a significant unmet medical need.
You May Interested In
2026-08-19
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Nirma acquires majority stake in Glenmark Life Sciences
-
Japanese Plastics Market Accelerates its Shifts to Recycled Materials and Bioplastics
-
SK Chemicals Partners with China’s Kelinle to Build Its Own Waste-Plastic Supply Network
-
Tinci Materials Calls Off 2.65 Billion Yuan Project as Electrolyte Giant Shifts Strategy
-
Eastern Shenghong Projects First-Half Profit of 5 Billion Yuan – A Collective Turnaround for the Four Major Private Refiners? Is the Chemical Sector Rebounding?
-
U.S. Chemical Tariff Deadline Nears as the Industry Faces Cost Repricing and Supply-Chain Adjustment
-
EU Finalizes Anti-Dumping Duties on Chinese Adipic Acid as Chemical Trade Enters a Rule-Intensive Phase
-
FDA Clears Sanofi’s Wayrilz (rilzabrutinib) for Adult ITP; U.S. Launch in September
-
EU Biocidal Data Protection Extension Raises the Stakes for Chemical Market Entry
-
API Supplier Audits Move to the Center of Pharma Supply Resilience
Recommend Reading
-
EFSA Finds Lavender Tincture Feed Additive Safe for All Animals
-
EU Alerts on Non-Compliant Chinese Oyster Sauce and Miso Exports
-
Supplement Recall Puts Nutrition Ingredient Safety Back Under Pressure
-
EFSA Publishes Peer Review on Fungicide Prothioconazole
-
Chung Lien Oil’s 8,000-Ton Soybean Oil BaP Scandal: NT$165 Million Fine, 401 Product Recalls, Source Still Unknown
-
Ammonium Sulfate Market Stably Operates in China (11.1-11.6)
-
Rate of Change Turns Positive—Retail Prices for Refined Oil Products to Be Raised in This Round
-
Cost-side support weakens, polyester staple fiber prices slightly decline
-
This Week's Epichlorohydrin Market Trading Focus Downward (11.3-11.6)
-
Multiple cycles at all-time lows! Melamine to remain in a narrow, weakly oscillating range in the short term